$157 Million is the total value of Nan Fung Group Holdings Ltd's 39 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 14.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRTX | Buy | KARUNA THERAPEUTICS INC | $54,352,000 | +90.4% | 241,639 | +7.1% | 34.69% | +76.9% |
| ILMN | ILLUMINA INC | $22,741,000 | +3.5% | 119,196 | 0.0% | 14.51% | -3.8% | |
| HRMY | Sell | HARMONY BIOSCIENCES HLDGS IN | $22,631,000 | -27.0% | 510,978 | -19.7% | 14.44% | -32.2% |
| Buy | EXSCIENTIA PLCads | $7,004,000 | -16.5% | 853,050 | +10.8% | 4.47% | -22.4% | |
| SGEN | SEAGEN INC | $6,444,000 | -22.7% | 47,096 | 0.0% | 4.11% | -28.1% | |
| SOMALOGIC INC | $4,920,000 | -35.8% | 1,696,558 | 0.0% | 3.14% | -40.4% | ||
| RANI THERAPEUTICS HLDGS INC | $4,729,000 | -7.3% | 493,584 | 0.0% | 3.02% | -13.8% | ||
| XENE | XENON PHARMACEUTICALS INC | $4,129,000 | +18.7% | 114,380 | 0.0% | 2.64% | +10.3% | |
| EAR | EARGO INC | $3,031,000 | +39.6% | 2,886,724 | 0.0% | 1.94% | +29.8% | |
| REPL | REPLIMUNE GROUP INC | $2,680,000 | -1.2% | 155,199 | 0.0% | 1.71% | -8.2% | |
| INCY | INCYTE CORP | $2,292,000 | -12.3% | 34,391 | 0.0% | 1.46% | -18.5% | |
| KDNY | New | CHINOOK THERAPEUTICS INC | $2,240,000 | – | 113,950 | +100.0% | 1.43% | – |
| Sell | ENTRADA THERAPEUTICS INC | $2,232,000 | +5.6% | 141,593 | -18.4% | 1.42% | -1.9% | |
| ISEE | Sell | IVERIC BIO INC | $2,009,000 | -12.1% | 111,984 | -52.8% | 1.28% | -18.3% |
| CCXI | CHEMOCENTRYX INC | $1,851,000 | +108.4% | 35,830 | 0.0% | 1.18% | +93.6% | |
| BOLT | BOLT BIOTHERAPEUTICS INC | $1,727,000 | -27.5% | 1,166,952 | 0.0% | 1.10% | -32.6% | |
| BGNE | BEIGENE LTDsponsored adr | $1,621,000 | -16.7% | 12,022 | 0.0% | 1.04% | -22.6% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $1,142,000 | +47.4% | 78,720 | 0.0% | 0.73% | +37.0% | |
| STSA | Buy | SATSUMA PHARMACEUTICALS INC | $1,067,000 | +80.2% | 177,900 | +24.5% | 0.68% | +67.3% |
| GRTX | GALERA THERAPEUTICS INC | $1,067,000 | +33.9% | 613,223 | 0.0% | 0.68% | +24.5% | |
| EXEL | EXELIXIS INC | $1,007,000 | -24.7% | 64,200 | 0.0% | 0.64% | -30.0% | |
| PACB | PACIFIC BIOSCIENCES CALIF IN | $841,000 | +31.4% | 144,840 | 0.0% | 0.54% | +22.0% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $657,000 | -30.5% | 370,950 | 0.0% | 0.42% | -35.5% | |
| 2SEVENTY BIO INC | $586,000 | +10.2% | 40,273 | 0.0% | 0.37% | +2.5% | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $518,000 | +2.2% | 6,115 | 0.0% | 0.33% | -4.9% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $491,000 | +16.4% | 29,984 | 0.0% | 0.31% | +7.9% | |
| ASND | ASCENDIS PHARMA A/Ssponsored adr | $430,000 | +11.1% | 4,168 | 0.0% | 0.27% | +3.0% | |
| ALXO | ALX ONCOLOGY HLDGS INC | $401,000 | +18.3% | 41,950 | 0.0% | 0.26% | +9.9% | |
| ARGX | ARGENX SEsponsored adr | $392,000 | -6.9% | 1,110 | 0.0% | 0.25% | -13.5% | |
| OTIC | Sell | OTONOMY INC | $251,000 | -85.8% | 851,000 | -0.0% | 0.16% | -86.8% |
| RETA | REATA PHARMACEUTICALS INCcl a | $208,000 | -17.1% | 8,265 | 0.0% | 0.13% | -22.7% | |
| RLMD | New | RELMADA THERAPEUTICS INC | $209,000 | – | 5,642 | +100.0% | 0.13% | – |
| FGEN | FIBROGEN INC | $192,000 | +23.1% | 14,756 | 0.0% | 0.12% | +15.0% | |
| AFMD | AFFIMED N V | $167,000 | -25.8% | 81,172 | 0.0% | 0.11% | -31.0% | |
| KOD | KODIAK SCIENCES INC | $152,000 | +1.3% | 19,622 | 0.0% | 0.10% | -5.8% | |
| ABCL | ABCELLERA BIOLOGICS INC | $124,000 | -6.8% | 12,521 | 0.0% | 0.08% | -13.2% | |
| SYBX | SYNLOGIC INC | $65,000 | -17.7% | 68,634 | 0.0% | 0.04% | -24.1% | |
| CERS | CERUS CORP | $51,000 | -32.0% | 14,172 | 0.0% | 0.03% | -36.5% | |
| NVTA | INVITAE CORP | $28,000 | 0.0% | 11,337 | 0.0% | 0.02% | -5.3% | |
| TCRR | Exit | TCR2 THERAPEUTICS INC | $0 | – | -19,335 | -100.0% | -0.04% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -3,917 | -100.0% | -0.20% | – |
| Exit | HASHICORP INC | $0 | – | -13,001 | -100.0% | -0.26% | – | |
| SNOW | Exit | SNOWFLAKE INCcl a | $0 | – | -19,210 | -100.0% | -1.84% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KARUNA THERAPEUTICS INC | 10 | Q3 2023 | 34.7% |
| HARMONY BIOSCIENCES HLDGS IN | 10 | Q3 2023 | 21.3% |
| XENON PHARMACEUTICALS INC | 10 | Q3 2023 | 3.1% |
| BOLT BIOTHERAPEUTICS INC | 10 | Q3 2023 | 5.6% |
| GALERA THERAPEUTICS INC | 10 | Q3 2023 | 1.9% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q3 2023 | 1.8% |
| EXELIXIS INC | 10 | Q3 2023 | 1.1% |
| DBV TECHNOLOGIES S A | 10 | Q3 2023 | 0.6% |
| ALX ONCOLOGY HLDGS INC | 10 | Q3 2023 | 1.0% |
| ILLUMINA INC | 9 | Q3 2023 | 21.5% |
View Nan Fung Group Holdings Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eargo, Inc. | December 16, 2022 | 2,958,099 | 0.7% |
| Stealth BioTherapeutics Corp | January 09, 2020 | 20,240,817 | 4.8% |
| New Frontier Health Corp | January 02, 2020 | 9,650,000 | 7.3% |
View Nan Fung Group Holdings Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-16 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
View Nan Fung Group Holdings Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.